Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 11/20 | 0.60 |
| ▸ | NPC1 | O15118 | 9/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11840192 | 0.83 | RAB9A (0.52) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL283737 | 0.83 | RAB9A (0.51) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL29372377 | 0.83 | RAB9A (0.51) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL8986532 | 0.83 | RAB9A (0.59) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL1197755 | 0.83 | TSHR (0.53) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL1503823 | 0.83 | RAB9A (0.57) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL29883001 | 0.81 | PTK2 (0.62) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL356367 | 0.81 | PTK2 (0.62) | RAB9ANPC1TSHRMEN1KMT2A | |
| SCHEMBL11845438 | 0.81 | RAB9A (0.59) | RAB9ANPC1MAPTTSHRMEN1 | |
| SCHEMBL6613670 | 0.80 | RAB9A (0.62) | RAB9ANPC1MAPTTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | GILEAD SCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250325677-A1 | STAT6 DEGRADERS | GILEAD SCIENCES INC (US) | 2025-10-23 | — | — | US | disclosed |
| CN-112608299-A | Synthesis method of 4- (6-aminopyridine-3-yl) piperidine-1-tert-butyl formate | 山东铂源药业有限公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-112608299-A | Synthesis method of 4- (6-aminopyridine-3-yl) piperidine-1-tert-butyl formate | 山东铂源药业有限公司 | 2021-04-06 | — | — | CN | disclosed |
| WO-2016161282-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-0938476-B1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6291489-B1 | USEFUL IN THE SYNTHESIS OF CERTAIN .BETA.-ADRENERGIC RECEPTOR AGONISTS | PFIZER INC. | 2001-09-18 | — | — | US | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0938476-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998021184-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325677-A1 | STAT6 DEGRADERS | STAT6, STAT5B, STAT1 | RAB9A 4378/4885NPC1 2139/4885MAPT 1017/4885 |
| US-20250340551-A1 | SMALL MOLECULE MODULATORS OF STAT6 | STAT6, STAT1, STAT5B | RAB9A 3014/4885NPC1 1677/4885MAPT 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.